Cargando…
Quality Assessment for PCR-based Minimal Residual Disease in Lymphoma: 10 Years of Cross-laboratory Standardization Process Within the Fondazione Italiana Linfomi MRD Network
Autores principales: | Mantoan, Barbara, Genuardi, Elisa, Ferrante, Martina, Della Starza, Irene, Ciabatti, Elena, Grassi, Susanna, De Novi, Lucia Anna, Cavalli, Marzia, Mannu, Claudia, Gazzola, Anna, Bomben, Riccardo, Degan, Massimo, Alessandria, Beatrice, Pott, Christiane, Delfau-Larue, Marie-Hélène, García-Sanz, Ramon, Agostinelli, Claudio, Gattei, Valter, Galimberti, Sara, Del Giudice, Ilaria, Gaidano, Gianluca, Ladetto, Marco, Ferrero, Simone, Drandi, Daniela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423385/ https://www.ncbi.nlm.nih.gov/pubmed/34514343 http://dx.doi.org/10.1097/HS9.0000000000000639 |
Ejemplares similares
-
Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma
por: Ferrero, Simone, et al.
Publicado: (2022) -
P1245: CLINICAL IMPACT OF IMMUNOGLOBULIN HEAVY CHAIN REPERTOIRE IN MANTLE CELL LYMPHOMA: A STUDY FROM THE FONDAZIONE ITALIANA LINFOMI (FIL) PHASE III MCL0208 TRIAL.
por: Alessandria, B., et al.
Publicado: (2022) -
Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the Fondazione Italiana Linfomi MCL0208 trial
por: Ferrero, Simone, et al.
Publicado: (2023) -
A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial
por: Zaccaria, Gian Maria, et al.
Publicado: (2021) -
A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial
por: Bomben, Riccardo, et al.
Publicado: (2018)